For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240418:nRSR0429La&default-theme=true
RNS Number : 0429L Redx Pharma plc 18 April 2024
REDX PHARMA PLC
("Redx" or the "Company")
Share Purchases by a Director
Alderley Park, UK, 18 April 2024 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, targeted therapeutics for the treatment of fibrotic disease and
cancer today announces that it has been notified that Lisa Anson, Chief
Executive Officer, has on 16 and 17 April 2024 acquired 189,500 Redx ordinary
shares at a weighted average price of 10.01 pence per share. Following this,
Lisa Anson will hold 751,683 ordinary shares in the Company, representing 0.19
per cent. of the issued share capital.
Further information on the purchases is contained within the disclosure tables
below.
For further information, please contact:
Redx Pharma Plc T: +44 (0)1625 469 918
UK Headquarters
Caitlin Pearson, Head of Communications
ir@redxpharma.com (mailto:ir@redxpharma.com)
SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368 3550
Matt Davis/ Adam Dawes
Panmure Gordon (UK) Limited (Broker) T: +44 (0)207 886 2500
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting T: +44 (0)203 727 1000
Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, targeted therapeutics
for the treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to clinical
proof of concept before evaluating options for further development and
potential value creation. The Company expects a number of data points during
2024 including from lead fibrosis product candidate, the selective ROCK2
inhibitor, zelasudil (RXC007), in development for interstitial lung disease
and currently undertaking a Phase 2a trial for idiopathic pulmonary fibrosis
(IPF). The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK
inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1
development and is expected to report healthy volunteer data; and Redx's lead
oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004),
being developed as a targeted treatment for Wnt-ligand dependent cancers, is
expected to report anti-PD-1 combination Phase 2 data, following which Redx
will seek a partner for ongoing development.
The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its wholly-owned clinical-stage
product candidates and discovery pipeline, but also by its strategic
transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the
only non-covalent or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz Pharmaceuticals.
To subscribe to Email Alerts from Redx, please
visit: www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/) .
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities (PDMR) / person
closely associated
a) Name Lisa Anson
2. Reason for the notification
a) Position / status Chief Executive Officer
b) Initial notification / Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Redx Pharma plc
b) LEI 213800HMS4EBXO589Y37
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1 pence each in Redx Pharma plc
Identification code ISIN for Redx Pharma plc Ordinary Shares:
GB00BSNB6S51
b) Nature of the transaction Purchase of Ordinary Shares
c) Prices(a) and volume(s)
Purchase Price per Ordinary Share Volume
9.375 pence 115,000 Ordinary Shares
d) Aggregated information
- Aggregated volume 115,000
- Price 9.375p
e) Date of the transaction 16 April 2024
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
d)
Aggregated information
- Aggregated volume
- Price
115,000
9.375p
e)
Date of the transaction
16 April 2024
f)
Place of the transaction
London Stock Exchange, AIM Market (XLON)
1. Details of the person discharging managerial responsibilities (PDMR) / person
closely associated
a) Name Lisa Anson
2. Reason for the notification
a) Position / status Chief Executive Officer
b) Initial notification / Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Redx Pharma plc
b) LEI 213800HMS4EBXO589Y37
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1 pence each in Redx Pharma plc
Identification code ISIN for Redx Pharma plc Ordinary Shares:
GB00BSNB6S51
b) Nature of the transaction Purchase of Ordinary Shares
c) Prices(a) and volume(s)
Purchase Price per Ordinary Share Volume
11 pence 74,500 Ordinary Shares
d) Aggregated information
- Aggregated volume 74,500
- Price 11p
e) Date of the transaction 17 April 2024
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
d)
Aggregated information
- Aggregated volume
- Price
74,500
11p
e)
Date of the transaction
17 April 2024
f)
Place of the transaction
London Stock Exchange, AIM Market (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFLFFDSFIDLIS